Benefits
Improved gait speed and physical function in older adults
An RCT in older adults (mean age 71) over 16 weeks showed GlyNAC supplementation increased gait speed by 19% and improved physical function vs placebo (alanine isonitrogenous control), along with improved muscle strength and exercise capacity. Notable for translating biochemical changes (glutathione restoration) to functional outcomes that matter for healthspan.
Restored intracellular glutathione (red cells, muscle)
GlyNAC supplementation restored intracellular glutathione to youthful levels in older adults. Older adults at baseline had severe GSH deficiency (red cells, muscle); GlyNAC normalized levels to those of young adult controls. This biomarker change is the mechanistic foundation for downstream functional improvements.
Reduced oxidative stress (TBARS -80%)
The trial documented an 80% reduction in TBARS (thiobarbituric acid reactive substances, a marker of lipid peroxidation/oxidative stress), with other markers (F2-isoprostanes) similarly improved. The magnitude of effect is unusual for a nutritional intervention, reflecting glutathione's central role in cellular antioxidant defense.
Improved insulin resistance (HOMA-IR -68%)
GlyNAC showed a 68% reduction in HOMA-IR (homeostatic model assessment of insulin resistance), a substantial improvement in glucose metabolism. Mechanism is via restored mitochondrial fatty acid oxidation and reduced oxidative-stress effects on insulin signaling. Important for metabolic health in aging.
Reduced inflammation (IL-6 -83%, TNF-α -58%)
The trial documented dramatic reductions in inflammatory cytokines: IL-6 down 83%, TNF-α down 58%, a magnitude comparable to some prescription anti-inflammatory drugs. Follow-up work showed GlyNAC reduces postprandial inflammation and oxidative stress after carbohydrate meals, important for daily exposure to dietary stressors.
Aging hallmarks improvement (multiple)
The trial measured multiple aging hallmarks including mitochondrial dysfunction, mitophagy, inflammation, insulin resistance, endothelial dysfunction, and body composition, with multiple hallmarks improving on GlyNAC supplementation. While the specific magnitude varies by hallmark, the multi-mechanism improvement is unusual (most aging interventions affect 1-2 hallmarks), suggesting a fundamental biochemical correction (glutathione deficiency) underlies multiple aging features.
Mechanism of action
Glutathione synthesis support — Sekhar's central hypothesis
Glutathione (γ-glutamyl-cysteinyl-glycine) requires three amino acids: glutamate, cysteine, glycine. Cysteine (delivered as NAC for stability and bioavailability) and glycine are the rate-limiting precursors in older adults. Sekhar's research showed older adults have severe GSH deficiency not primarily due to enzymatic problems but due to precursor deficiency. Providing glycine + NAC restores GSH synthesis to youthful levels.
Mitochondrial function restoration
Glutathione is critical for mitochondrial function: protects mtDNA from ROS damage, maintains complex I activity, supports mitophagy (clearance of damaged mitochondria). Restored GSH improves mitochondrial fatty-acid oxidation (MFO) and ATP production. Mechanism for energy/strength improvements observed in trials.
Reduced oxidative damage to proteins, lipids, DNA
Glutathione directly scavenges ROS and supports glutathione peroxidase (GPx) activity. Reduces oxidative damage to membrane lipids (lipid peroxidation, TBARS), proteins (carbonylation), and DNA (8-oxo-dG). Mechanism for multiple downstream functional benefits.
NF-κB inhibition and inflammatory cytokine reduction
Oxidative stress activates NF-κB. Restoring glutathione/redox balance reduces NF-κB activation, decreasing IL-6, TNF-α, IL-1β. Mechanism for the dramatic anti-inflammatory effects observed in Sekhar trials — particularly relevant to 'inflammaging' in older adults.
Glycine independent benefits (sleep, GABA-glycine receptor)
Glycine has independent effects beyond glutathione synthesis: NMDA co-agonist, glycine receptor activity in CNS (sleep quality support, neuroprotection), substrate for collagen and creatine synthesis. Some clinical effects of GlyNAC may reflect glycine-specific benefits separate from glutathione restoration.
Clinical trials
Randomized double-blind placebo-controlled trial (Kumar P, Liu C, Suliburk J, Hsu JW, Muthupillai R, Jahoor F, Minard CG, Taffet GE, Sekhar RV 2022, J Gerontol A Biol Sci Med Sci 78(1):75-89, doi:10.1093/gerona/glac135).
24 older adults (mean age 71y) randomized to GlyNAC (glycine 1.33 mmol/kg/d + NAC 0.83 mmol/kg/d) or isonitrogenous placebo (alanine) for 16 weeks. 12 young adults (mean age 25y) received GlyNAC for 2 weeks as comparison. Measurements: intracellular GSH, oxidative stress, mitochondrial function, inflammation, insulin resistance, endothelial function, physical function, body composition, aging hallmarks.
Older adults at baseline had: severe GSH deficiency (red cells and muscle vs young adults), mitochondrial dysfunction, elevated oxidative stress (TBARS, F2-isoprostanes), reduced gait speed and exercise capacity, elevated waist circumference, insulin resistance, endothelial dysfunction. GlyNAC supplementation results: restored GSH to youthful levels, improved mitochondrial fatty-acid oxidation, reduced TBARS by 80%, IL-6 by 83%, TNF-α by 58%, HOMA-IR by 68%; increased gait speed by 19% and improved physical function. Multiple aging hallmarks improved. No significant adverse effects. Foundational pivotal clinical trial for GlyNAC supplementation in aging.
Postprandial clinical trial (follow-up gerontology research).
20 older adults and 10 young adults given 75 g oral glucose test meal with assessment of 2-hour postprandial change in TBARS and IL-6. Repeated and compared after subjects received their assigned supplements (GlyNAC vs placebo).
Baseline: older adults had significantly higher 2-hour postprandial increases in oxidative stress and inflammation vs young adults (TBARS: YA 0.02 vs OA 1.09, p=0.03; IL-6: YA 0.03 vs OA 0.52, p<0.001). After GlyNAC supplementation: protected older adults from glucose-meal-driven oxidative stress and inflammation rises. Important real-world finding — GlyNAC provides protection against daily dietary oxidative-inflammatory challenges, not just baseline biomarker correction.
Multiple smaller pilot studies preceding the 2022 clinical trial (Sekhar lab, Baylor College of Medicine). Including studies in HIV patients with premature aging, animal models, and metabolic syndrome contexts.
Various smaller cohorts including aged mice, HIV-infected adults with premature aging features, and pilot human studies.
Established GlyNAC effects on glutathione restoration, mitochondrial function, oxidative stress, and metabolic markers in multiple populations and species. Animal studies showed GlyNAC improved age-related deficits in aged mice including GSH, MFO, insulin resistance. Foundation for the pivotal 2022 clinical trial that translated preclinical findings to randomized human evidence.